Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study

被引:0
|
作者
Escobar, Carlos [1 ]
Palacios, Beatriz [2 ]
Villarreal, Miriam [2 ]
Gutierrez, Martin [2 ]
Capel, Margarita [3 ]
Aranda, Unai [4 ]
Hernandez, Ignacio [5 ]
Garcia, Maria [5 ]
Lledo, Laura [5 ]
Arenillas, Juan F. [6 ,7 ]
机构
[1] Univ Hosp La Paz, Dept Cardiol, Madrid 28046, Spain
[2] AstraZeneca, BioPharmaceut Med, Madrid 28050, Spain
[3] AstraZeneca, BioPharmaceut Corp Affairs & Market Access, Madrid 28050, Spain
[4] AstraZeneca, BioPharmaceut Med, Global Med Affairs, Gaithersburg, MD 20878 USA
[5] Atrys Hlth, Madrid 28002, Spain
[6] Hosp Clin Univ, Comprehens Stroke Ctr, Neurol Dept, Valladolid 47003, Spain
[7] Univ Valladolid, Dept Med, Clin Neurosci Res Grp, Valladolid 47003, Spain
关键词
atrial fibrillation; cost; direct oral anticoagulants; healthcare resource utilization; major bleeding; reversal agents; venous thromboembolism; ORAL ANTICOAGULANTS; ATRIAL-FIBRILLATION; WARFARIN; RIVAROXABAN; GUIDELINE; APIXABAN; EDOXABAN; SAFETY;
D O I
10.3390/jcm13144253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Our aims were to describe the clinical characteristics, adverse clinical events, healthcare resource utilization (HCRU) and costs of patients with major bleeding during direct Factor Xa inhibitor (FXai) use. Methods: This is a retrospective cohort study that included secondary data from computerized health records of seven Spanish Autonomous Communities. Patients with a first major bleeding during treatment with a direct FXai were analyzed during a 3-year period. Results: Of 8972 patients taking a direct FXai, 470 (5.24%) had major bleeding (mean age (SD) 77.93 (9.71) years, 61.06% women). The most frequent indications for using FXais were atrial fibrillation (78.09%) and venous thromboembolism (17.66%). Among those with major bleeding, 88.94% presented with gastrointestinal bleeding, 6.81% intracranial bleeding, 2.13% trauma-related bleeding and 4.26% other major bleeding. Prothrombin complex concentrates were used in 63.19%, followed by transfusion of blood products (20.21%) and Factor VIIa (7.66%). In total, 4.26% of patients died in the hospital due to the first major bleeding. At the study end (after 3-year follow-up), 28.94% of the patients had died, 12.34% had a myocardial infarction and 9.15% an ischemic stroke. At year 3, overall bleeding cost was EUR 5,816,930.5, of which 79.74% accounted for in-hospital costs to treat the bleeding episode. Conclusions: Despite the use of replacement agents being high, major events were common, with a 29% mortality at the end of the follow up, and HCRU and costs were high, evidencing the need for new reversal treatment strategies.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study
    Escobar, Carlos
    Palacios, Beatriz
    Villarreal, Miriam
    Gutierrez, Martin
    Capel, Margarita
    Hernandez, Ignacio
    Garcia, Maria
    Lledo, Laura
    Arenillas, Juan F.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [2] Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors
    Deitelzweig, Steven
    Neuman, W. Richey
    Lingohr-Smith, Melissa
    Menges, Brandy
    Lin, Jay
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (12) : 1217 - 1223
  • [3] Clinical and Economic Impact of a First Major Bleeding Event in Non-Anticoagulated Patients in Spain: A 3-Year Retrospective Observational Cohort Study
    Escobar, Carlos
    Palacios, Beatriz
    Villarreal, Miriam
    Gutierrez, Martin
    Capel, Margarita
    Hernandez, Ignacio
    Garcia, Maria
    Lledo, Laura
    Arenillas, Juan F.
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [4] Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors
    Sie, P.
    Samama, C. -M.
    Godier, A.
    Rosencher, N.
    Steib, A.
    Llau, J. -V.
    van der Linden, P.
    Pernod, G.
    Lecompte, T.
    Gouin-Thibault, I.
    Albaladejo, P.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2011, 30 (09): : 645 - 650
  • [5] Clinical impact of major bleeding in patients with venous thrombo-embolism treated with factor Xa inhibitors or vitamin K antagonists
    Bleker, Suzanne M.
    Brekelmans, Marjolein P. A.
    Eerenberg, Elise S.
    Cohen, Alexander T.
    Middeldorp, Saskia
    Raskob, Gary
    Buller, Harry R.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (10) : 1944 - 1951
  • [6] The incidence of death and risk factors for mortality following major bleeding in patients anticoagulated with factor Xa inhibitors: an observational study in the UK clinical setting (AXIOM UK)
    Cohen, A.
    Er, C.
    Mamza, J. B.
    He, G.
    Hussain, K.
    Stamp, N.
    Choudhuri, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [7] The incidence of death and risk factors for mortality following major bleeding in patients anticoagulated with factor Xa inhibitors: an observational study in the UK clinical setting (AXIOM UK)
    Cohen, A.
    Er, C.
    Mamza, J. B.
    He, G.
    Hussain, K.
    Stamp, N.
    Choudhuri, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [8] Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013
    Pernod, Gilles
    Albaladejo, Pierre
    Godier, Anne
    Samama, Charles M.
    Susen, Sophie
    Gruel, Yves
    Blais, Normand
    Fontana, Pierre
    Cohen, Ariel
    Llau, Juan V.
    Rosencher, Nadia
    Schved, Jean-Francois
    de Maistre, Emmanuel
    Samama, Meyer M.
    Mismetti, Patrick
    Sie, Pierre
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (6-7) : 382 - 393
  • [9] Short-term incidence of thrombotic events in patients who were treated with factor Xa inhibitors and hospitalized for bleeding
    Wu, Chuntao
    Hasan, Jawad
    Smith, William
    Rumantir, Ryan A.
    Li, Michael O.
    Cole, Alexander
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 629 - 629
  • [10] Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice
    Lukasik, Maria
    Zawilska, Krystyna
    Undas, Anetta
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2015, 49 (03) : 171 - 179